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A B S T R A C T
Objective: The Disproportionate Intrauterine Growth Intervention Trial at Term (DIGITAT trial) showed
that in women with suspected intrauterine growth restriction (IUGR) at term, there were no substantial
outcome differences between induction of labour and expectant monitoring. The objective of the present
analysis is to evaluate whether maternal or fetal markers could identify IUGR fetuses who would beneﬁt
from early labour induction.
Study design: The DIGITAT trial was a multicenter, parallel and open-label randomised controlled trial in
women who had a singleton pregnancy beyond 36 + 0 weeks’ gestation with suspected IUGR (n = 650).
Women had been randomly allocated to either labour induction or expectant monitoring. The primary
outcome was a composite measure of adverse neonatal outcome, deﬁned as neonatal death before
hospital discharge, Apgar score <7, umbilical artery pH <7.05, or admission to neonatal intensive care.
Using logistic regression modelling, we investigated associations between outcome and 17 markers,
maternal characteristics and fetal sonographic and Doppler velocimetry measurements, all collected at
study entry.
Results: 17 (5.3%) infants in the induction group had an adverse neonatal outcome compared to 20 (6.1%)
in the expectant monitoring group. The only potentially informative marker for inducing labour was
maternal pre-pregnancy body mass index (BMI). Otherwise, we observed at best weak associations
between a beneﬁt from labour induction and maternal age, ethnicity, smoking, parity, pregnancy-
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(gender, estimated fetal weight, body measurements, oligohydramnios, or umbilical artery pulsatility
index and end diastolic ﬂow).
Conclusion: In late preterm and term pregnancies complicated by suspected intrauterine growth
restriction, most of the known prognostic markers seem unlikely to be helpful in identifying women who
could beneﬁt from labour induction, except for maternal pre-pregnancy BMI.
 2013 Elsevier Ireland Ltd. All rights reserved.Fig. 1. Trial proﬁle.1. Introduction
Intrauterine growth restriction (IUGR) refers to a condition
where the fetus has failed to achieve its intrinsic growth potential
due to anatomical and/or functional disorders and diseases in the
feto–placental–maternal unit. IUGR affects 5–10% of pregnancies
and is associated with an increased risk of perinatal mortality and
morbidity, neurodevelopmental deﬁcits during childhood and a
range of diseases in adult life.
A management option for term IUGR fetuses is delivery, to
release the fetus from the potentially inadequate environment.
Expectant monitoring with maternal and fetal monitoring is the
alternative commonly followed strategy. The Disproportionate
Intrauterine Growth Intervention Trial At Term (DIGITAT trial)
compared labour induction with expectant monitoring in women
who had a singleton pregnancy beyond 36 + 0 weeks with
suspected IUGR [1,2]. The trial included 650 women and
demonstrated that there are no substantial differences in outcome
between induction of labour and expectant monitoring; 5.3% of
fetuses in the labour induction group had an adverse neonatal
outcome versus 6.1% in the expectant monitoring group. Caesarean
section and instrumental vaginal delivery rates were also
comparable in the treatment groups.
In practice, obstetricians are often willing to induce labour in
term IUGR pregnancies for fear of still-birth, especially in the
presence of maternal risk factors, abnormal fetal sonographic
measurements or abnormalities of fetal Doppler velocimetry [3].
At present, there is no evidence from randomised trials on
whether selecting patients for labour induction based on
maternal or fetal risk factors improves perinatal and maternal
outcomes. We undertook a post hoc exploratory analysis of the
DIGITAT trial data, to evaluate which maternal or fetal
characteristics are more likely to be helpful in identifying
patients who could beneﬁt from labour induction, compared to
expectant monitoring.
2. Materials and methods
2.1. Study design and patients
The background of the trial, methods, and baseline character-
istics of the randomised women has been previously reported
elsewhere [2,4]. In brief, the trial included 650 pregnant women
between 36 + 0 and 41 + 0 weeks’ gestation, who had a singleton
fetus in a cephalic presentation, suspected IUGR, and were under
specialised obstetric care with no contraindication to vaginal
delivery. Suspected IUGR was deﬁned as fetal abdominal
circumference below the 10th percentile, estimated fetal weight
below the 10th percentile, ﬂattening of the growth curve in the
third trimester (as judged by a clinician), or the presence of a
combination of any of these three factors [5].
Eligible and consenting women were randomly allocated to
either labour induction (n = 321) or expectant monitoring (n = 329)
(Fig. 1). In the induction group, labour was induced within 48 h
after randomisation. In the expectant monitoring group, women
were monitored until the onset of spontaneous delivery or deliveryindications, such as suboptimal fetal heart rate tracings, prolonged
rupture of membranes, postmaturity, or occurrence of severe
preeclampsia.
The primary outcome was a composite measure of adverse
neonatal outcome, combining the occurrence of neonatal death
before hospital discharge, ﬁve-minute Apgar score of less than 7,
umbilical artery pH of less than 7.05, or admission to neonatal
intensive care. For each participating woman, 50 maternal and
fetal characteristics were measured and recorded before rando-
misation at baseline. Based on a review of the literature and expert
opinion, we selected 17 markers which were reportedly prognostic
and therefore could have potentially been informative for
treatment selection. For maternal markers we selected age, pre-
pregnancy body mass index (BMI), Caucasian ethnicity, smoking,
parity, presence of pregnancy-induced hypertension or pre-
eclampsia in the current pregnancy, gestational age and Bishop
score at randomisation. For fetal markers we evaluated gender,
estimated weight (in percentiles, corrected for gestational age),
oligohydramnios, biparietal distance, head circumference, abdom-
inal circumference, femur length and umbilical artery pulsatility
index and end diastolic ﬂow. Fetal weight was estimated by the
Hadlock formula [6] and the percentiles were determined using
the Kloosterman’s growth charts [7].
2.2. Data analysis
For each marker we developed a logistic regression model to
predict the composite adverse neonatal outcome by marker,
treatment, and marker-by-treatment interaction. The latter term
expresses to what extent the treatment effect is associated with
the marker value. In this context, we deﬁne that markers could be
potentially useful for treatment selection if they show a biologi-
cally plausible qualitative interaction with treatment [8]. A marker
has a qualitative interaction with treatment if it is risk factor (odds
ratio >1) in one arm of trial and protective factor in the other arm
of trial (odds ratio <1). The presence of a qualitative interaction
would imply that for a subgroup of fetuses labour induction is
Table 1
Maternal and fetal characteristics of the participants in DIGITAT trial at study entry.
Baseline characteristics Expectant monitoring (n = 329) % missing Labour induction (n = 321) % missing
Maternal demographic and clinical characteristics
Age (years)a 27 (23–31) 0 27 (23–31) 0
Body mass index (kg/m2)a 22 (20–26) 10 22 (20–26) 14
Non-smoker (%) 48.3 9 48.3 11
Caucasian ethnicity (%) 76.9 5 76.9 5
Nulliparity (%) 61.1 0 61.1 0
Pregnancy-induced hypertension (%) 5.8 0 5.8 0
Pre-eclampsia (%) 8.2 0 8.2 0
Bishop scorea 2 (1–4) 8 2 (1–4) 7
Foetal conditions
Male foetus (%) 37.1 0 38.3 0
Gestational age (days)a 37.6 (36.8–38.5) 0 37.6 (36.8–38.5) 0
Estimated weight percentile (%) 15 21
<3rd percentile 15.0 12.4
3–5th percentile 21.6 22.9
5–10th percentile 36.9 35.0
>10th percentile 26.1 29.7
Oligohydramnios (%) 34.8 9 31.1 13
Biparietal distance percentilea 27 (20–41) 24 27 (20–41) 24
Head circumference percentilea 30 (21–41) 12 30 (21–41) 17
Abdominal circumference percentilea 9 (5–13) 5 9 (5–13) 6
Femur length percentilea 14 (7–22) 7 14 (7–22) 7
Pulsatility index of the umbilical arterya 0.9 (0.8–1.1) 16 0.9 (0.8–1.1) 18
Absent umbilical artery end diastolic ﬂow 2.7 20 2.5 13.7
a Median (interquartile range).
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beneﬁcial. Given the exploratory nature of our analysis, we focus
on the magnitude of the interaction and the associated precision,
not on statistical hypothesis testing. All analyses were done using R
for Windows (Version 2.11.1; R Foundation for Statistical
Computing, Vienna, Austria).Table 2
The relationship between maternal characteristics and the occurrence of adverse neonata
in whom the labour was induced. For each biomarker, odds ratios (OR) show the relative
ratio of the two odds ratios.
Maternal characteristics Expectant monitoring 
Subgroup
size
Adverse neonatal
outcome (%)
Odds r
(95% C
Age (years)a 0.95 (0
15–25 118 9.3 (5–16) 
25–30 101 3.0 (1–9) 
30–42 110 5.4 (2–12) 
Body mass index (kg/m2)a 1.06 (1
15–20 80 2.5 (0–10) 
20–25 133 5.3 (2–11) 
25–33 82 11.0 (5–20) 
Ethnicity 1.15 (0
Caucasianb 253 5.9 (3–10) 
Non-Caucasian 59 6.8 (2–17) 
Smoker 0.75 (0
Yes 170 5.0 (2–10) 
Nob 159 6.9 (4–12) 
Parity 0.65 (0
Nulliparous 128 4.5 (2–11) 
Multiparousb 201 8.5 (5–14) 
Pregnancy-induced HTN or Pre-eclampsia 2.31 (0
Present 46 10.9 (4–24) 
Absentb 283 5.3 (3–9) 
Bishop scorea 0.96 (0
0–2 51 7.8 (3–20) 
2–4 113 5.3 (2–12) 
4–10 93 7.5 (3–15) 
a The odds ratios are calculated using the variables as a continuous factor and not 
purposes.
b Reference category.
c The interaction is qualitative; indicating that for example if the marker is risk facto
protective factor (odds ratio <1) under the labour induction strategy, or vice versa.3. Results
Baseline characteristics of the women and fetuses who
participated in the DIGITAT trial are summarised in Table 1.
Induction group infants were born 10 days earlier (95% CI: 9–11
days) and weighed 130 g less (95% CI: 77–188 g) than babies inl outcome is shown separately in women who underwent expectant monitoring and
 change in the risk per unit increase in the marker. The interaction OR presents the
Labour induction Interaction OR
atio
I)
Subgroup
size
Adverse neonatal
outcome (%)
Odds ratio
(95% CI)
.9–1.0) 0.94 (0.8–1.0) 1.01 (0.89–1.16)
113 8.0 (4–15)
113 4.4 (2–10)
95 3.2 (1–10)
.0–1.1)c 0.97 (0.9–1.1)c 1.09 (0.96–1.24)
79 7.6 (3–16)
122 6.7 (3–13)
74 4.0 (1–12)
.4–2.5)c 0.68 (0.2–2.5)c 1.69 (0.25–11.11)
254 5.9 (3–10)
50 4.0 (1–15)
.3–1.9) 0.88 (0.3–2.3) 0.86 (0.23–3.27)
180 5.0 (2–10)
141 5.7 (3–11)
.2–2.0) 0.31 (0.1–1.4) 2.08 (0.32–13.48)
125 3.4 (1–9)
196 8.1 (5–14)
.3–19.6) 1.06 (0.1–8.4) 1.99 (0.17–23.01)
27 7.4 (1–26)
294 5.1 (3–8)
.8–1.2) 0.93 (0.7–1.2) 1.04 (0.72–1.48)
48 2.1 (0–12)
117 6.0 (3–12)
109 4.6 (2–11)
a categorical factor. The categories presented here are just made for presentation
r (odds ratio >1) for the outcome under the strategy of expectant monitoring, it is
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occurred in the study. In the labour induction group 20 infants
(6.1%) had an adverse neonatal outcome compared to 17 (5.3%)
in the expectant monitoring group, which indicated that
induction of labour and expectant monitoring are comparable
in their risk of adverse neonatal outcome (0.8% risk difference;
95% CI: 4.3–3.2%).
Table 2 summarizes the results of our analysis of the
associations between maternal markers and treatment outcome.
In the expectant monitoring group, fetuses of younger mothers
were at a slightly higher risk of adverse neonatal outcome; the
older the mother, the lower the risk (odds ratio (OR) 0.95),
but this association was also present in women in whom labour
was induced (OR 0.94). These ﬁndings do not suggest that
maternal age could be informative for the choice of labour
induction.
In contrast, the pre-pregnancy maternal BMI could potential-
ly be informative for the choice of treatment. In the expectant
monitoring group, a higher pre-pregnancy BMI was associated
with a higher risk of adverse neonatal outcome (OR 1.06), while
in the labour induction group the higher BMI was associated
with a lower risk (OR 0.97). This implies that fetuses of mothers
with high pre-pregnancy BMI might beneﬁt from labourTable 3
The relationship between fetal characteristics and the occurrence of adverse neonatal ou
whom the labour was induced. For each biomarker, odds ratios (OR) show the relative cha
of the two odds ratios.
Fetal characteristics Expectant monitoring 
Subgroup
size
Adverse neonatal
outcome (%)
Odds r
(95% C
Gender 1.40 (0
Male 107 8.4 (4–16) 
Femaleb 180 6.1 (3–11) 
Gestational agea 0.97 (0
36 wk 80 8.7 (4–18) 
37 wk 102 5.9 (2–13) 
 38 wk 101 6.9 (3–14) 
Estimated foetal weighta 1.52 (0
<3rd percentile 89 9.0 (4–17) 
3–5th percentile 69 5.8 (2–15) 
5–10th percentile 52 5.8 (2–17) 
10th percentile 76 6.6 (2–15) 
Oligohydramnios 1.58 (0
Present 101 8.3 (4–15) 
Absentb 194 5.2 (2–10) 
Biparietal distancea 1.00 (0
<10th percentile 14 0 (0–27) 
10th percentile 235 6.4 (4–11) 
Head circumferencea 1.02 (1
<10th percentile 14 0 (0–27) 
10th percentile 275 6.6 (4–10) 
Femur lengtha 1.01 (0
<10th percentile 107 6.5 (3–13) 
10th percentile 195 5.6 (3–10) 
Abdominal circumferencea 1.01 (0
<10th percentile 185 4.9 (2–9) 
10th percentile 126 7.1 (4–14) 
Umbilical artery pulsatility index (UA-PI)a 1.47 (0
<0.9 105 5.7 (2–13) 
0.9–1.1 101 3.8 (1–10) 
1.1 71 8.4 (3–18) 
Umbilical artery end diastolic ﬂow 2.49 (0
Presentb 255 6.4 (4–10) 
Absent 7 16.7 (1–60) 
Reversed 0 – 
NA: not available.
a The odds ratios are calculated using the variables as a continuous factor and not 
purposes.
b Reference category.
c The interaction is qualitative; indicating that for example if marker A is a risk factor (
factor (OR < 1) under the labour induction strategy, or vice versa.induction, while fetuses of normal and low BMI mothers might
be better off with expectant monitoring. Fetuses of non-
caucasian mothers were at higher risk of adverse neonatal
outcome when monitored expectantly (OR 1.15), but the risk
was reduced in the labour induction group (OR 0.68). Ethnicity
might therefore also be a potential marker for the choice of
treatment. We found no other qualitatively differential marker-
treatment association, suggesting that it is unlikely that
maternal smoking status, parity, hypertensive disorders of
pregnancy, Bishop score and gestational age could have any
potential for treatment selection.
Table 3 presents the 10 investigated fetal markers and their
association with the risk of adverse neonatal outcome in the two
management strategies. Male fetus, lower estimated fetal weight,
presence of oligohydramnios and elevated umbilical artery
pulsatility index were factors generally associated with a mild
increase in the risk of adverse neonatal event, but we did not
observe that induction of labour could reduce the increased risk of
these fetuses. Absence of umbilical artery end diastolic ﬂow was
seen in only 2.6% of fetuses and due to the very small size of the
subgroup we have limited precision in evaluating a differential
association with treatment outcome, and to assess if this could be
helpful for treatment selection. None of the studied fetal bodytcome is shown separately in women who underwent expectant monitoring and in
nge in the risk per unit increase in the marker. The interaction OR presents the ratio
Labour induction Interaction OR
atio
I)
Subgroup
size
Adverse neonatal
outcome (%)
Odds ratio
(95% CI)
.6–3.5) 1.87 (0.7–5.0) 0.74 (0.20–2.85)
105 8.6 (4–16)
174 4.6 (2–9)
.7–1.3) 0.91 (0.6–1.4) 1.06 (0.61–1.86)
77 6.5 (2–15)
99 6.1 (2–13)
103 5.8 (2–13)
.6–3.9) 2.00 (0.6–6.5) 0.76 (0.45–4.2)
39 10.3 (3–25)
72 5.7 (2–14)
75 6.7 (2–16)
93 4.3 (1–11)
.6–4.1) 1.31 (0.5–3.5) 1.21 (0.41–5.9)
87 7.9 (3–16)
192 6.1 (3–11)
.9–1.1) 0.99 (0.9–1.1) 1.01 (0.97–1.05)
24 8.3 (1–28)
208 5.87 (3–10)
.0–1.1) 0.98 (0.9–1.0) 1.04 (0.98–1.09)
11 9.1 (0–43)
256 5.5 (3–9)
.9–1.1) 0.98 (0.9–1.1) 1.03 (0.98–1.09)
106 6.6 (3–14)
192 5.2 (3–10)
.9–1.1) 0.90 (0.8–1.0) 1.12 (0.99–1.27)
169 7.7 (4–13)
134 3.0 (1–8)
.2–12.0) 1.08 (0.1–9.2) 1.37 (0.05–35.88)
87 3.4 (1–10)
89 9.0 (4–17)
86 5.8 (2–14)
.3–1.9)c 0 (0–NA)c NA
270 6.8 (4–11)
7 0 (0–44)
0 –
a categorical factor. The categories presented here are just made for presentation
OR > 1) for the outcome under the strategy of expectant monitoring, it is protective
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who could beneﬁt from inducing labour.
4. Comments
In this study of late preterm and term growth-restricted fetuses
we could investigate the potential of 17 well-known maternal and
fetal risk factors of adverse neonatal outcome for identiﬁcation of
fetuses who could beneﬁt from labour induction. Maternal pre-
pregnancy BMI was the most promising factor, leading to the
hypothesis that, in late-preterm IUGR, labour induction might be
beneﬁcial in women with a high pre-pregnancy BMI. Our analysis
also suggested that in women of non-caucasian ethnicity labour
induction might be beneﬁcial, but the small size of this subgroup
and the relatively rare outcome do not allow us to make ﬁrm
statements.
Overall, the lack of precision is more of a problem with binary
risk factors that are not very common, like umbilical artery end
diastolic ﬂow. We are aware of this limitation, but considered it
worthwhile to explore the association between the markers and
the beneﬁt from labour induction, for producing hypotheses for
treatment selection that can be tested and validated in future
studies.
Our analysis is based on a randomised trial data of 650 IUGR-
suspected pregnancies, where patients had been randomly
allocated to expectant monitoring strategy or immediate labour
induction. There was no selection bias: none of the evaluated
baseline maternal and fetal risk factors had affected the choice of
treatment.
A considerable proportion of small for gestational age (SGA)
fetuses are constitutionally small and not at increased risk of
perinatal morbidity and mortality. In the remaining proportion of
SGA fetuses, growth is pathologically restricted, mainly due to
placental insufﬁciency. Finding markers that could identify
growth-restricted fetuses would therefore be valuable, especially
if earlier delivery of these fetuses reduces their expected high risk
of adverse perinatal outcomes. A series of physiological markers
have been proposed, such as sex or maternal age, height, body
mass index, ethnicity and parity [10,11]. If an SGA fetus is female or
from a non-caucasian, nulliparous mother with short height or low
weight, the chances that it is constitutionally small are considered
to be higher [12]. Our analysis supports this hypothesis about
gender of fetus, nulliparity and maternal pre-pregnancy BMI, but
only pre-pregnancy BMI seems to be potentially useful for
treatment selection.
In general, there is an inverse relationship between fetal weight
percentile and adverse perinatal outcomes. In a recent study by
Pilliod and colleagues, the risk of intrauterine fetal death in non-
anomalous fetuses under the 3rd percentile of weight was as high
as 58 per 10,000 versus 5 per 10,000 in non-IUGR fetuses [13].
Although the risk is more than 10 times that of the non-IUGR fetus,
the difference in the risk is as small as 0.5%. We also observed in our
study participants that fetuses with an estimated weight under the
3rd percentile were at slightly higher risk of adverse neonatal
outcomes compared to other IUGR fetuses, but labour induction
could not reduce this risk. These fetuses are generally at a slightly
higher risk, and early delivery by labour induction does not seem to
change this risk.
In a systematic review and meta-analysis of six good-quality
trials, Westergaard and colleagues concluded that the use of
umbilical artery Doppler velocimetry in pregnancies with
suspected IUGR and/or hypertensive disease of pregnancy
reduces the number of perinatal deaths and unnecessary
obstetrics interventions [14]. A comparison of our patient
population with that of their pooled analysis shows that the
systematic review included higher risk pregnancies; the perinataldeath rate in the pooled analysis was about 2%, where we had no
perinatal death in 650 patients. Their meta-analysis included
women as early in their pregnancy as 24 weeks, which may
contribute to the higher risk of perinatal mortality and also to the
observed beneﬁt of umbilical artery Doppler velocimetry. There
are other proposed biomarkers such as measures of fetal brain
vasodilatation that might be helpful for identifying fetuses that
would beneﬁt from interventions [15–17] but these needs to be
evaluated in similar studies before they can be applied in clinical
practice.
At present there is no single test that dictates the optimal
timing of delivery of the growth restricted fetus. In practice, term
pregnancies are often delivered and the delivery of the late
preterm (34 + 0–36 + 6 weeks) or early term (37 weeks) growth-
restricted fetus is also recommended if there are additional risk
factors for adverse outcome, such as maternal medical/obstetrical
disorders, arrest of growth over a three- to four-week interval, and/
or absence or reversal Doppler ﬂow in the umbilical artery [9]. This
strategy is based on the consensus that the growth-restricted fetus
should be born if the empirically estimated risk of fetal death
exceeds the risk of neonatal death. The DIGITAT trial shows that
the risk of neonatal morbidity and mortality in suspected growth-
restricted fetuses of 36 weeks and later is rather small, provided
there is adequate fetal monitoring. Except for maternal pre-
pregnancy body mass index, none of the markers evaluated here
seems to be informative about the beneﬁt of labour induction in
this population and setting.
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